NASDAQ · IRD
Opus Genetics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IRD: Nov 11, 2026
Opus Genetics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.08 | $-0.19 | 7 |
| Dec 2026 | $-0.07 | $0.19 | $-0.19 | 7 |
| Mar 2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · Fintel · RTTNews · Zacks- MarketBeat · Oct 25, 8:02 AM EDTOpus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval5 Space Stocks That Could Soar in the Next DecadeOpus Genetics (NASDAQ:IRD) outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its funding strategy during an investor panel fe
- Fintel · Oct 21, 5:00 PM EDTOpus Genetics, Inc. Announces Transition of Chief Scientific and Development Officer Ashwath JayagopalOpus Genetics, Inc. and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company’s Chief Scientific and Development Officer, effective as of October 19, 2026. Effective on the Separation Date, the Company entered into a separation and re
- RTTNews · Sep 29, 5:33 AM EDTBiotech Stocks Facing FDA Decision In October 2026(RTTNews) – The FDA's October decision calendar looks relatively light, with only a limited number of PDUFA dates scheduled.
- Fintel · Sep 15, 6:33 PM EDTOpus Genetics Consensus Price Target Increased 21.47% to $12.98The average one-year price target for Opus Genetics (NASDAQCM:IRD) has been revised to $12.98 / share. This is an increase of 21.47% from the prior estimate of $10.68 dated August 25, 2026. These figures represent aggregate analyst targets compiled from multiple sources and do n
- RTTNews · Sep 9, 2:36 PM EDTClinical Catalysts Drive Biotech Movers: Opus Genetics, Quantum & More(RTTNews) – Biotech and medical device stocks saw notable moves Wednesday, led by Opus Genetics, which surged more than 27% following positive clinical data. Quantum BioPharma gained after receiving FDA clearance for a Phase 2 MS trial, while Pulse Biosciences rallied more than 1
- RTTNews · Sep 9, 8:32 AM EDTOpus Genetics Reports Positive OPGx-BEST1 Data; Plans Potential Phase 3 Trial In 2027(RTTNews) – Opus Genetics, Inc. (IRD) announced positive 3- and 6-month results from Cohort 1 of its ongoing Phase 1/2 BIRD-1 clinical trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases, including Best vitelliform macular dystrophy (BVMD) and autosomal re
- RTTNews · Aug 19, 9:16 PM EDTLongeveron Appoints Jhaveri As CFO Ahead Of Phase 2b Data; Stock Up(RTTNews) – Longeveron Inc. (LGVN), a clinical-stage biotech company focused on developing cellular therapies for rare paediatric and chronic age-related diseases, on Wednesday announced the appointment of Nirav Jhaveri as Chief Financial Officer (CFO).
- Zacks · Aug 6, 8:20 AM EDTOpus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue EstimatesOpus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 8:35 PM EDTQiagen (QGEN) Beats Q2 Earnings and Revenue EstimatesQiagen (QGEN) delivered earnings and revenue surprises of +3.33% and +1.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 6, 11:00 AM EDTOpus Aligns With FDA On Phase 3 Study For OPGx-LCA5 In Treating IRD; Dosing To Begin In Q4(RTTNews) – Opus Genetics Inc. (IRD), a clinical-stage biopharmaceutical company, on Monday announced achieving alignment with the U.S. Food and Drug Administration (FDA) on the Phase 3 registrational trial on OPGx-LCA5 in treating inherited retinal dystrophy in a Type B Rare Dis
- RTTNews · Jul 6, 7:30 AM EDTOpus Genetics Confirms FDA Alignment On Phase 3 Study Design To Evaluate OPGx-LCA5(RTTNews) – Opus Genetics (IRD) has reached alignment with the FDA in a Type B Rare Disease Evidence Principles meeting on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5 for LCA5-associated inherited retinal disease. The company has received the meet
- RTTNews · Jun 17, 6:09 AM EDTOpus Releases Updates On Gene Therapies For Retinal Diseases; OPGx-LCA5 Phase 3 Set For Q4 '26(RTTNews) – Opus Genetics Inc. (IRD), a clinical-stage biopharmaceutical company, on Tuesday provided updates on various gene therapies under development for the treatment of inherited retinal diseases (IRDs). The data was presented at the Research and Development (R&D) Science F
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Opus Genetics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.